This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Arizona Cancer Center

Get an overview of the diagnostic criteria and key clinical trials for Philadelphia chromosome–negative classical myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. Learn about the role of the JAK-STAT signaling pathway, as well as strategies for optimizing the selection and sequencing of treatments for patients with myeloproliferative neoplasms.


Download Slides

These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.